Teva announced that the New England Journal of Medicine published the results of its Phase 3 SPACE study on January 14 2026, showing that AJOVY (fremanezumab‑vfrm) reduces migraine frequency in children and adolescents.
The 12‑week, randomized, placebo‑controlled trial found that AJOVY lowered monthly migraine days by 2.5 days versus 1.4 days with placebo, and 47.2% of patients achieved a ≥ 50% reduction compared with 27.0% on placebo. The safety profile was consistent with adult data, with no new safety signals identified in the pediatric cohort.
This publication marks the first CGRP antagonist approved for preventive treatment of episodic migraine in the 6‑to‑17‑year‑old, 45‑kg‑plus population, filling a critical unmet need and expanding Teva’s migraine portfolio into a new, sizable market segment.
"The SPACE trial confirms that a CGRP‑targeted therapy can meaningfully reduce migraine frequency in young patients and provide physicians with much‑needed guidance for this underserved population," said Dr. Andrew D. Hershey, lead author and director of neurology at Cincinnati Children’s Hospital Medical Center. "These results strengthen the evidence for AJOVY and expand on its well‑established benefits in adults, reflecting Teva’s commitment to innovation for the migraine community," added Dr. Eric Hughes, executive vice president of global R&D and chief medical officer.
Teva’s FDA approval of AJOVY for pediatric use in August 2025 and the NEJM publication reinforce the company’s “Pivot to Growth” strategy, which focuses on high‑margin innovative medicines such as AJOVY, AUSTEDO, and UZEDY. The company has reported consecutive quarters of growth in its innovative portfolio and is actively reducing net debt to EBITDA, positioning it for long‑term profitability.
Analysts continue to view Teva’s expanded migraine portfolio favorably, citing the strong clinical data and the company’s track record of executing on its growth strategy. The publication of the SPACE study is expected to reinforce confidence in Teva’s pipeline and support its ongoing efforts to capture a larger share of the migraine market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.